BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT06253195 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
Hormone-receptor-positive Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
HER2-negative Breast Cancer

Interventions

DRUG: BGB-43395
DRUG: Fulvestrant
DRUG: Letrozole

Sponsor

BeiGene